Company news

Zentalis Pharmaceuticals, Inc. news in 2022

Zentalis Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates

November 8, 2022

Zentalis Pharmaceuticals to Participate in the Stifel 2022 Healthcare Conference

November 7, 2022

Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer

October 23, 2022

Zentalis Pharmaceuticals Appoints Dr. Mark Lackner as Chief Translational Officer, Head of Biomarker Strategy

October 16, 2022

Zentalis Pharmaceuticals Promotes Co-Founder Kevin Bunker, Ph.D. to Chief Scientific Officer

September 26, 2022

Zentalis Pharmaceuticals Appoints Dr. Carrie Brownstein as Chief Medical Officer

September 18, 2022

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

September 11, 2022

Zentalis Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update

August 8, 2022

Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Conference

August 2, 2022

Zentalis Pharmaceuticals, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 31, 2022

Zentalis Pharmaceuticals Appoints Andrea Paul as General Counsel and Corporate Secretary

June 26, 2022

Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President

May 30, 2022

Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock

May 17, 2022

Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer

May 15, 2022

Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update

May 4, 2022

Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer

April 26, 2022

Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR

April 10, 2022

Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR

April 7, 2022

Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3

March 28, 2022

Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis

March 21, 2022

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update

February 23, 2022

Decks in 2022